Cigna capitalizes on commercial growth as net income jumps 55%

A bar chart showing positive business growth
Cigna's strong first quarter was backed by continued growth in the commercial market. (Getty/NicoElNino)

While its competitors are cashing in on Medicare Advantage plans, Cigna has seen strong revenue growth in its commercial business lines.

That growth led to a solid first-quarter earnings report, as the company looks to close its acquisition of pharmacy benefit manager Express Scripts by the end of the year.

Cigna beat estimates with $11.4 billion in revenue in the first quarter of 2018, a 9% increase compared to the same quarter last year. Net income soared to $917 million, a 55% increased over the $593 million reported in the first three months last year.


2019 Drug Pricing and Reimbursement Stakeholder Summit

Given federal and state pricing requirements arising, press releases from industry leading pharma companies, and the new Drug Transparency Act, it is important to stay ahead of news headlines and anticipated requirements in order to hit company profit targets, maintain value to patients and promote strong, multi-beneficial relationships with manufacturers, providers, payers, and all other stakeholders within the pricing landscape. This conference will provide a platform to encourage a dialogue among such stakeholders in the pricing and reimbursement space so that they can receive a current state of the union regarding regulatory changes while providing actionable insights in anticipation of the future.

Most of that was driven by strong growth in commercial plans, which added 518,000 members compared to the same time last year. The Bloomfield, Connecticut-based insurer saw significant growth among smaller businesses with 50-500 employees, reporting 14% year-over-year growth.

Commercial premiums jumped 16% compared to the first quarter last year, accounting for nearly $5 billion in the first three months. 

Cigna ended the quarter with 401,000 on individual plans, including 338,000 through the Affordable Care Act exchanges.

RELATED: Aetna rides Medicare Advantage growth, ACA exit to profitable Q1

That growth was offset by losses within the insurer’s government plans, which haven’t fared as well. The company saw a 2% decline in Medicare-covered lives compared to the first quarter last year. 

That could change in the coming years, however, as Cigna looks to re-establish its presence in the Medicare Advantage market. Last year, the Centers for Medicare & Medicaid Services (CMS) lifted sanctions tied to violations of coverage determinations, appeals, and grievances.

Cigna CEO David Cordani indicated last year that the company was interested in building up its Medicare Advantage offerings through acquisitions. On Thursday's earnings call, Cordani recognized a future growth opportunity in converting commercial members to MA plans, noting that the company is well-positioned to execute on that strategy in 2019.

“That’s a future growth opportunity that’s not lost on us in any way shape or form,” he said.

RELATED: DOJ taking a closer look at Cigna-Express Scripts merger

Cigna executives continued to make their case for the Express Scripts deal, pointing to increasing drug costs, particularly for specialty drugs. Cordani emphasized the merger would provide better-coordinated care and “deeper alignment across critical elements of the health system” that would “directly benefit customers and clients.”

That deal, which the company expects to close by the end of the year, is being closely scrutinized by the Department of Justice.

Suggested Articles

Health insurers’ financial performance is on a continuing upward trend, but political and legal risks could pose a threat to that growth.

Senate lawmakers released a draft package of legislation Thursday aimed at curbing health care costs they said they believe they can pass on a bipartisan basis…

Attorneys general seeking to defend the ACA argue that their opponents—including the DOJ—have poor legal standing to challenge the law.